Catalyst Pharmaceuticals (CPRX) Q3 2024 earnings summary

Executive summary

• Achieved Q3 2024 total revenues of $128.7 million, up 25.3% year-over-year, driven by strong Firdapse and Agamree performance.

• Expanded product portfolio and global reach, including Agamree launch and Firdapse approval in Japan.

• Maintained robust liquidity with $442.3 million in cash and equivalents at quarter-end.

• Settled key patent litigation, strengthening intellectual property protection for Firdapse and Fycompa.

• Focused on business development and potential acquisitions to further diversify rare disease portfolio.

Financial highlights

• Q3 2024 net product revenues: $126.4 million, up 23.2% year-over-year; total revenue $128.7 million.

• Firdapse Q3 net sales: $79.3 million (+19.7% YoY); Agamree: $15 million; Fycompa: $32.1 million (-11.9% YoY).

• GAAP net income: $43.9 million ($0.35/diluted share) vs. net loss of $38.8 million in Q3 2023.

• Non-GAAP net income: $71.1 million ($0.57/diluted share) vs. non-GAAP net loss of $25.6 million in Q3 2023.

• Ended Q3 with $442.3 million in cash and equivalents, up from $137.6 million at 2023 year-end.

Outlook and guidance

• Full-year 2024 revenue guidance raised to $475–$485 million.

• Firdapse 2024 net revenue guidance narrowed to $300–$310 million.

• Agamree 2024 net revenue guidance increased to $40–$45 million.

• Fycompa 2024 net revenue guidance reaffirmed at $130–$135 million.

• Sufficient cash to fund operations for at least 12 months; ongoing focus on expanding product portfolio and global footprint.